1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Analysis & Statistics in European Union, January 2018 (p4)

Cancer Analysis & Statistics in European Union, January 2018 (p4)

Customer Support

Talk to Ahmad

+1 718 618 4302

All regions

91-120 of about 100 reports

Drug Analysis: darolutamide

  • $ 10000
  • January 2018
  • 17 pages

Drug Overview Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens ...

  • Cancer
  • Hormone
  • Prostate Cancer
  • Therapy
  • European Union

Drug Analysis: DCVAC/PCa

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed ...

  • Cancer
  • Cell Therapy
  • Medical Biotechnology
  • Prostate Cancer
  • European Union

Drug Analysis: Zytiga

  • $ 10000
  • January 2018
  • 21 pages

Drug Overview Zytiga (abiraterone acetate; Johnson and Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates ...

  • Cancer
  • Hormone
  • Therapy
  • European Union
  • Supply

Drug Analysis: Xtandi

  • $ 10000
  • January 2018
  • 19 pages

Drug Overview Xtandi (enzalutamide; Pfizer/Astellas) is an androgen receptor (AR) signaling inhibitor that inhibits the AR at three distinct points in the signaling pathway. Xtandi competitively inhibits ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Xofigo

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Tecentriq

  • $ 10000
  • January 2018
  • 82 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug Analysis: Masitinib

  • $ 10000
  • January 2018
  • 45 pages

Drug Overview Masitinib (AB Science) is an oral tyrosine kinase inhibitor being developed by AB Science. It targets a number of receptor tyrosine kinases including c-Kit, fibroblast growth factor recepto ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • Prostate Cancer
  • European Union

Drug Analysis: Jevtana

  • $ 10000
  • January 2018
  • 16 pages

Drug Overview Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) ...

  • Cancer
  • Prostate Cancer
  • European Union
  • Japan
  • United States

Drug analysis: Cotellic

  • $ 10000
  • December 2017
  • 26 pages

Drug Overview Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug analysis: Binimetinibi

  • $ 10000
  • December 2017
  • 27 pages

Drug Overview Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK ...

  • Cancer
  • Monoclonal Antibody
  • European Union
  • United States
  • Supply

Drug analysis: Erbitux

  • $ 10000
  • December 2017
  • 34 pages

Drug Overview Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR). The ...

  • Cancer
  • Medical Biotechnology
  • Therapy
  • European Union
  • Supply

Drug analysis: Opdivo

  • $ 10000
  • December 2017
  • 103 pages

Drug Overview Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor that binds to the checkpoint recepto ...

  • Cancer
  • Pathology
  • European Union
  • United States

Drug analysis: Vectibix

  • $ 10000
  • December 2017
  • 23 pages

Drug Overview Vectibix (panitumumab; Amgen/Takeda) is a fully human immunoglobulin G2 monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor (EGFR). This prevents ...

  • Cancer
  • Colorectal Cancer
  • Medical Biotechnology
  • European Union
  • Japan

Drug analysis: Encorafenib

  • $ 10000
  • December 2017
  • 27 pages

Drug Overview Encorafenib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is a RAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAF V600E. The drug was developed ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Gastric Cancer Forecast and Market Analysis to 2024

  • $ 22000
  • December 2017
  • 334 pages

Disease Overview Gastric cancer is the second-leading cause of cancer-related mortality worldwide. There is significant geographic variation in the burden of the disease: incidence and mortality are notably ...

  • Cancer
  • Gastric Cancer
  • European Union
  • Japan
  • United States

Drug analysis: Lonsurf

  • $ 10000
  • December 2017
  • 18 pages

Drug Overview Lonsurf ([trifluridine + tipiracil]; Otsuka/Servier) is an oral combination drug with both anti-angiogenic and cytotoxic effects. It is composed of trifluridine, an antineoplastic nucleoside ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • Japan

Drug analysis: Avastin

  • $ 10000
  • December 2017
  • 116 pages

Drug Overview Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF). The VEGF protein is an essential ...

  • Breast Cancer
  • Cancer
  • Pathology
  • European Union
  • Product Initiative

Drug analysis: Cyramza

  • $ 10000
  • December 2017
  • 56 pages

Drug Overview Cyramza (ramucirumab; Eli Lilly/Shire) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellula ...

  • Cancer
  • Colorectal Cancer
  • Lung Cancer
  • European Union
  • Supply

Drug analysis: Keytruda

  • $ 10000
  • December 2017
  • 120 pages

Drug Overview Keytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the programmed death-1 (PD-1) co-inhibitory receptor. The interaction between PD-1 and its primary ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Drug analysis: Stivarga

  • $ 10000
  • December 2017
  • 28 pages

Drug Overview Stivarga (regorafenib; Bayer/Amgen) is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor recepto ...

  • Cancer
  • Colorectal Cancer
  • Diagnostic Imaging
  • Magnetic Resonance Imaging
  • European Union

Drug analysis: Napabucasin

  • $ 10000
  • December 2017
  • 36 pages

Drug Overview Napabucasin (Dainippon Sumitomo) is designed to selectively and simultaneously inhibit multiple key pathways associated with tumor growth and development by targeting the STAT3 transcription ...

  • Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Pathology
  • European Union

Colorectal Cancer Forecast and Market Analysis to 2036

  • $ 22000
  • December 2017
  • 650 pages

Disease Overview Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiato ...

  • Cancer
  • Colorectal Cancer
  • Pathology
  • European Union
  • United States

Drug Analysis: Gilotrif

  • $ 10000
  • December 2017
  • 31 pages

Drug Overview Gilotrif is an orally administered TKI that irreversibly binds to EGFR/human epidermal growth factor receptor 1 (HER1), HER2, and HER4. In cancerous cells where EGFR and HER2 receptors are ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • United States

Drug Analysis: Imfinzi

  • $ 10000
  • December 2017
  • 41 pages

Drug Overview AstraZeneca’s Imfinzi is a human monoclonal antibody targeting PD-L1. Programmed death-1 (PD-1) and its ligands, PD-L1 and PD-L2, are members of the cluster of differentiation (CD)28 and ...

  • Bladder Cancer
  • Cancer
  • Lung Cancer
  • Pathology
  • European Union

Drug Analysis: Bavencio

  • $ 10000
  • December 2017
  • 64 pages

Drug Overview Bavencio is a fully human MAb targeting the PD-L1 protein. The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), regulates complex signaling pathways that affect T-cell ...

  • Cancer
  • Lung Cancer
  • Pathology
  • European Union
  • Japan

Multiple Myeloma Disease Coverage Forecast and Market Analysis to 2024

  • $ 22000
  • October 2017
  • 488 pages

DISEASE OVERVIEW Multiple myeloma is characterized by the infiltration of malignant, antibody-producing plasma cells in the bone marrow. Almost all cases occur in individuals aged over 40 years, and age ...

  • Cancer
  • Pathology
  • European Union
  • Japan
  • United States

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • June 2017
  • 69 pages

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin ...

  • Cancer
  • Cervical Cancer
  • Pathology
  • European Union
  • Japan

Non-small cell lung cancer (NSCLC) disease forecast and market analysis to 2035

  • $ 22000
  • March 2017
  • 549 pages

Disease Overview Lung cancer is a disease in which the cells in lung tissue grow uncontrollably. More than 80% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending ...

  • Cancer
  • Lung Cancer
  • European Union
  • Japan
  • Demand

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016

  • $ 3500
  • November 2016
  • 69 pages

Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Thrombopoietin Receptor (Myeloproliferative ...

  • Cancer
  • Hospital
  • Therapy
  • European Union
  • Product Initiative

Gastric cancer

  • $ 5000
  • July 2016
  • 249 pages

Pipeline therapies will look to fulfil many areas of high unmet need left by the lack of targeted therapies approved for the treatment of gastric cancer. This report addresses the following questions: - ...

  • Cancer
  • European Union
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Roche Group

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on